Eagle Genomics raises £1m from London Business Angels and other investors to support product development and marketing.
The Cambridge-based bioinformatics specialist has closed a £1m investment round backed by London Business Angels.
Share allotment filed at Companies House
Eagle Genomics is a bioinformatics company based in Cambridge that provides software solutions to accelerate research and development in the life sciences sector.
Eagle Genomics has secured £1m in a new funding round backed by London Business Angels and other investors, including the LBA EIS Roundtable Syndicate Fund 2016. The Cambridge-based bioinformatics specialist develops software that helps pharmaceutical, biotech, and personal care companies accelerate product development and reduce research costs for clients such as Unilever.
The capital from this growth round will be directed towards expanding the firm's marketing efforts and enhancing its product development capabilities. Existing and new angel investors participated in the raise, positioning the company to scale its operations further.
Investor perspective
"Eagle Genomics which is now at scale up stage is commercialising an effective bioinformatics software solution that has the potential to improve the way in which new medicines and therapies are developed. This round of growth capital funding from existing and new angel investors leaves the company well positioned to accelerate its growth in this fast growing market."
Anthony Clarke
CEO, London Business Angels
Use of funds
- 01Continue product development
- 02Invest in sales and marketing
Investors
Categories
About the company
Eagle Genomics
Eagle Genomics develops bioinformatics software for pharmaceutical and life science research.